Characteristics and Predictors of Central Nervous System Relapse in Newly Diagnosed Acute Promyelocytic Leukemia in the Era of Arsenic: a 13-year Monocenter Cohort Study

Overview

Journal Blood Cancer J

Date 2025 Mar 16

PMID 40089468

Authors

Bingqian Jiang

Hongyan Tong

Haitao Meng

Wanzhuo Xie

Wenjuan Yu

Jian Huang

Huafeng Wang

Liangshun You

Liping Mao

Min Yang

Jiejing Qian

Yanling Ren

Chunmei Yang

Liya Ma

Jie Jin

Yinjun Lou

Affiliations

Soon will be listed here.

References

Voso M, Guarnera L, Lehmann S, Lehmann S, Dohner K, Dohner H . Acute promyelocytic leukemia: long-term outcomes from the HARMONY project. Blood. 2024; 145(2):234-243. DOI: 10.1182/blood.2024026186. View

Tallman M . Treatment of relapsed or refractory acute promyelocytic leukemia. Best Pract Res Clin Haematol. 2007; 20(1):57-65. DOI: 10.1016/j.beha.2006.11.002. View

Specchia G, Coco F, Vignetti M, Avvisati G, Fazi P, Albano F . Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto. J Clin Oncol. 2001; 19(20):4023-8. DOI: 10.1200/JCO.2001.19.20.4023. View

Ravandi F . Prophylactic intrathecal chemotherapy in acute promyelocytic leukemia (APL). Leukemia. 2004; 18(4):879-80. DOI: 10.1038/sj.leu.2403306. View

Montesinos P, Diaz-Mediavilla J, Deben G, Prates V, Tormo M, Rubio V . Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica. 2009; 94(9):1242-9. PMC: 2738716. DOI: 10.3324/haematol.2009.007872. View

Zhu H, Wu D, Jin J, Li J, Ma J, Wang J . Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol. 2013; 31(33):4215-21. DOI: 10.1200/JCO.2013.48.8312. View

Cheson B, Cassileth P, Head D, Schiffer C, Bennett J, Bloomfield C . Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990; 8(5):813-9. DOI: 10.1200/JCO.1990.8.5.813. View

Wang H, Cao F, Li J, Li L, Li Y, Shi C . Arsenic trioxide and mannitol for the treatment of acute promyelocytic leukemia relapse in the central nervous system. Blood. 2014; 124(12):1998-2000. PMC: 4168355. DOI: 10.1182/blood-2014-04-568121. View

Ohanian M, Rozovski U, Ravandi F, Garcia-Manero G, Jabbour E, Kantarjian H . Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia. Br J Haematol. 2014; 169(4):595-7. PMC: 4414662. DOI: 10.1111/bjh.13230. View

10.

De Botton S, Sanz M, Chevret S, Dombret H, Martin G, Thomas X . Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia. 2005; 20(1):35-41. DOI: 10.1038/sj.leu.2404006. View

11.

Tashiro H, Shirasaki R, Oka Y, Sugao T, Mizutani-Noguchi M, Yamamoto T . FLT3 internal tandem duplication is associated with a high relapse rate and central nervous system involvement in acute promyelocytic leukemia cases: single institutional analysis. Eur J Haematol. 2010; 86(3):272-3. DOI: 10.1111/j.1600-0609.2010.01559.x. View

12.

Gale R, Hills R, Pizzey A, Kottaridis P, Swirsky D, Gilkes A . Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood. 2005; 106(12):3768-76. DOI: 10.1182/blood-2005-04-1746. View

13.

Sanz M, Coco F, Martin G, Avvisati G, Rayon C, Barbui T . Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood. 2000; 96(4):1247-53. View